Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
NVCT
#3038
Nuvectis Pharma, Inc. Common Stock
8.8
6
-0.78%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
-0.78%
Monatliche Änderung
+0.68%
6 month change
+32.24%
Jahresänderung
+27.85%
Vorheriger Schlusskurs
8.9
3
Open
8.8
6
Bid
Ask
Low
8.8
6
High
8.8
6
Volumen
17
Märkte
Aktien
Gesundheitswesen
NVCT
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Dividends per share
—
0
—
—
—
0
—
Dividend yield %
—
0
—
—
—
0
—
Payout ratio %
—
0
—
—
—
0
—
Nachrichten
Nuvectis, NXP900 ile osimertinib kombinasyonunu değerlendiren Faz 1b çalışmasını başlattı
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib
H.C. Wainwright, Nuvectis Pharma için Al notunu yineledi
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright
Kaplan, Nuvectis Pharma (NVCT) hisselerinden 64.240 dolar değerinde satın aldı
Nuvectis Pharma başkanı Bentsur 28.600 dolarlık hisse alımı gerçekleştirdi
Nuvectis Pharma yöneticisi Sanchez, NVCT hisselerinden 75 bin dolarlık alım yaptı
H.C. Wainwright, Nuvectis Pharma hissesi için Al tavsiyesini 10 dolar hedefle yineledi
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target
Nuvectis Pharma adds former Intra-Cellular exec to board of directors
Nuvectis initiates phase 1b program for cancer drug NXP900
Nuvectis (NVCT) Q2 Loss Widens 43%